living donor renal transplantation
Conditions
Interventions
a four-drug combination therapy :Patients underwent treatment with a four-drug combination therapy consisting of tacrolimus, MMF, corticosteroid mizoribine.
a three -drug combination therapy :Patients underwent treatment with a three-drug combination therapy consisting of tacrolimus, MMF corticosteroid.
Sponsors
Henan Provincial Peoples Hospital
Eligibility
Sex/Gender
All
Age
17 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. ABO-identical or compatible living donor renal transplantation; 2. 17 to 60 years of age; 3. No consideration to be given to gender, age, or underlying disease; 4. Patients are willing to sign informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with serious infections or cardiac diseases; 2. Women who are pregnant or seeking to become pregnant during the study period; 3. Patients with white blood cell count <3000/mm3; 4. Patients who have a history of allergies to any investigational product (FK-506, MMF, MZR) or steroids; 5. Cases that have been determined by the study principal study investigators to be unsuitable for administration of the study drugs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence rates of acute rejection;The occurrence of calcineurin inhibitor-induced renal damage;The incidence rates of adverse effects such as diarrhea caused by MMF; | — |
Secondary
| Measure | Time frame |
|---|---|
| the incidence rates of other adverse effects; | — |
Countries
China
Contacts
Public ContactTian-zhong Yan
Outcome results
None listed